IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i9p5122-d800063.html
   My bibliography  Save this article

Implementation of Interventions and Policies on Opioids and Awareness of Opioid-Related Harms in Canada: A Multistage Mixed Methods Descriptive Study

Author

Listed:
  • Camille Goyer

    (Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada
    YolaRX Consultants, Montreal, QC H3W 1Y7, Canada)

  • Genaro Castillon

    (YolaRX Consultants, Montreal, QC H3W 1Y7, Canada)

  • Yola Moride

    (YolaRX Consultants, Montreal, QC H3W 1Y7, Canada
    Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA)

Abstract

In Canada, interventions and policies have been implemented to minimize the risk of opioid-related harms. This mixed methods study aimed at describing trends over time in implementation, as well as in awareness and health outcomes. For implementation, we conducted a scoping review to identify opioids interventions and policies implemented in Canada between 1 January 2016 and 15 November 2019. Awareness was measured through a descriptive analysis of opioid-related harm cases reported by consumers and health care professionals (HCPs) to the national spontaneous reporting system and of social media coverage, while health outcome consisted of opioid-related deaths recorded in the coroner’s reports database of the province of Quebec, Canada. Trends over time in implementation of interventions were compared to trends in awareness and opioid-related deaths, without implying causality. There were 413 national or provincial interventions on opioids implemented over the study period, with a four-fold increase in 2016. The most common (31.5%) was harm reduction strategies, such as naloxone distribution. The reporting rate of opioid-related harms ranged between 0.1 and 0.2 per 100,000 persons with no observed time trend. Compared to 2015, the number of social media posts increased in 2016 by 35.4% (Reddit), 329.0% (Facebook), and 381.5% (Twitter). Between 2016 and 2019, there was a slight decrease in the number of opioid-related deaths recorded in the coroner’s database. Overall, the increase in the number of policies did not see a parallel increase in spontaneous reports of opioid-related harms as an indicator of consumer or HCP awareness. Conversely, the dramatic increase in social media coverage was consistent with heightened public awareness. Although no inferences of causality were made in this study, the decrease in opioid-related deaths observed in the recent years may indicate a potential effectiveness of interventions and policies.

Suggested Citation

  • Camille Goyer & Genaro Castillon & Yola Moride, 2022. "Implementation of Interventions and Policies on Opioids and Awareness of Opioid-Related Harms in Canada: A Multistage Mixed Methods Descriptive Study," IJERPH, MDPI, vol. 19(9), pages 1-12, April.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:9:p:5122-:d:800063
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/9/5122/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/9/5122/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Meredith Y. Smith & Andrea Russell & Priya Bahri & Peter G. M. Mol & Sarah Frise & Emily Freeman & Elaine H. Morrato, 2018. "The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products," Drug Safety, Springer, vol. 41(4), pages 389-401, April.
    2. Carrie E. Pierce & Khaled Bouri & Carol Pamer & Scott Proestel & Harold W. Rodriguez & Hoa Le & Clark C. Freifeld & John S. Brownstein & Mark Walderhaug & I. Ralph Edwards & Nabarun Dasgupta, 2017. "Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts," Drug Safety, Springer, vol. 40(4), pages 317-331, April.
    3. Rania Mouchantaf & Doris Auth & Yola Moride & June Raine & Soon Young Han & Meredith Y. Smith, 2021. "Risk Management for the 21st Century: Current Status and Future Needs," Drug Safety, Springer, vol. 44(4), pages 409-419, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Andrea M. Russell & Elaine H. Morrato & Rebecca M. Lovett & Meredith Y. Smith, 2020. "Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review," Drug Safety, Springer, vol. 43(5), pages 427-446, May.
    2. Lucie M. Gattepaille & Sara Hedfors Vidlin & Tomas Bergvall & Carrie E. Pierce & Johan Ellenius, 2020. "Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project," Drug Safety, Springer, vol. 43(8), pages 797-808, August.
    3. Yiqing Zhao & Yue Yu & Hanyin Wang & Yikuan Li & Yu Deng & Guoqian Jiang & Yuan Luo, 2022. "Machine Learning in Causal Inference: Application in Pharmacovigilance," Drug Safety, Springer, vol. 45(5), pages 459-476, May.
    4. Juergen Dietrich & Lucie M. Gattepaille & Britta Anne Grum & Letitia Jiri & Magnus Lerch & Daniele Sartori & Antoni Wisniewski, 2020. "Adverse Events in Twitter-Development of a Benchmark Reference Dataset: Results from IMI WEB-RADR," Drug Safety, Springer, vol. 43(5), pages 467-478, May.
    5. Ying Li & Antonio Jimeno Yepes & Cao Xiao, 2020. "Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions," Drug Safety, Springer, vol. 43(9), pages 893-903, September.
    6. Karen Smith & Su Golder & Abeed Sarker & Yoon Loke & Karen O’Connor & Graciela Gonzalez-Hernandez, 2018. "Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab," Drug Safety, Springer, vol. 41(12), pages 1397-1410, December.
    7. Gianluca Trifirò & Janet Sultana & Andrew Bate, 2018. "From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources," Drug Safety, Springer, vol. 41(2), pages 143-149, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:9:p:5122-:d:800063. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.